Having trouble accessing articles? Reset your cache.

Tarceva erlotinib regulatory update

FDA approved an sNDA from Astellas for Tarceva erlotinib for first-line treatment in patients with metastatic non-small cell lung cancer (NSCLC)

Read the full 214 word article

User Sign In

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE